Protein Summary
ATP dependent phosphorylation of adenosine and other related nucleoside analogs to monophosphate derivatives. Serves as a potential regulator of concentrations of extracellular adenosine and intracellular adenine nucleotides. This gene an enzyme which catalyzes the transfer of the gamma-phosphate from ATP to adenosine, thereby serving as a regulator of concentrations of both extracellular adenosine and intracellular adenine nucleotides. Adenosine has widespread effects on the cardiovascular, nervous, respiratory, and immune systems and inhibitors of the enzyme could play an important pharmacological role in increasing intravascular adenosine concentrations and acting as anti-inflammatory agents. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2011]
- ENST00000286621
- ENSP00000286621
- ENSG00000156110
- ENST00000372734
- ENSP00000361819
- ENST00000539909
- ENSP00000443965
- ENST00000541550
- ENSP00000438321
- AK
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
transcription factor perturbation | 1 | ||
kinase perturbation | 0.99 | ||
molecular function | 0.96 | ||
transcription factor binding site profile | 0.96 | ||
biological process | 0.91 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 693.99 (req: < 5)
Gene RIFs: 17 (req: <= 3)
Antibodies: 405 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 693.99 (req: >= 5)
Gene RIFs: 17 (req: > 3)
Antibodies: 405 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 9
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 144
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0